PriceTargets.com logo

PolyPid - PYPD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.67
  • Forecasted Upside: 155.85%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$4.56 As of 06/17/2026 05:00 PM ET
▼ -0.1 (-2.15%)

This chart shows the closing price for PYPD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PolyPid Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PYPD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PYPD

Analyst Price Target is $11.67
▲ +155.85% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for PolyPid in the last 3 months. The average price target is $11.67, with a high forecast of $13.00 and a low forecast of $9.00. The average price target represents a 155.85% upside from the last price of $4.56.

This chart shows the closing price for PYPD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in PolyPid. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/20/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/19/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/18/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/1/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
2/11/2026HC WainwrightReiterated RatingBuy ➝ Buy$13.00
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025CitigroupReiterated RatingMarket Outperform ➝ Market Outperform
11/13/2025Roth MkmLower TargetBuy ➝ Buy$10.00 ➝ $9.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/14/2025Craig HallumReiterated RatingBuy ➝ Buy$15.00 ➝ $13.00
8/14/2025Roth MkmReiterated RatingBuy ➝ Buy
8/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$13.00
6/18/2025Roth MkmSet TargetBuy ➝ Buy$12.00 ➝ $9.00
6/17/2025Citizens JmpLower TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $14.00
6/9/2025HC WainwrightBoost TargetBuy ➝ Buy$11.00 ➝ $13.00
6/5/2025Roth MkmInitiated CoverageBuy$9.00
6/2/2025HC WainwrightUpgradeBuy$11.00
4/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
1/28/2025Rodman & RenshawUpgradeStrong-Buy
1/28/2025Rodman & RenshawInitiated CoverageBuy$13.00
12/26/2024HC WainwrightLower TargetBuy ➝ Buy$14.00 ➝ $11.00
12/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
11/4/2024Craig HallumInitiated CoverageBuy$10.00
10/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
8/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
6/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00
5/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00
10/12/2023HC WainwrightInitiated CoverageBuy
9/7/2022BarclaysDowngradeOverweight ➝ Equal Weight$660.00 ➝ $75.00
9/6/2022Raymond James FinancialDowngradeStrong-Buy ➝ Outperform$450.00 ➝ $120.00
8/11/2022BMO Capital MarketsLower TargetOutperform$810.00 ➝ $750.00
2/11/2022Raymond James FinancialLower TargetStrong-Buy$690.00 ➝ $510.00
12/16/2021Citizens JmpReiterated RatingBuy$450.00
10/11/2021Citizens JmpReiterated RatingBuy
9/14/2021Citizens JmpInitiated CoverageOutperform$420.00
7/30/2021Cantor FitzgeraldInitiated CoverageOverweight$720.00
(Data available from 6/18/2021 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2025
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2026
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2026

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
PolyPid logo
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Read More

Today's Range

Now: $4.56
Low: $4.56
High: $4.76

50 Day Range

MA: $4.60
Low: $4.12
High: $5.07

52 Week Range

Now: $4.56
Low: $3.06
High: $5.21

Volume

24,328 shs

Average Volume

142,216 shs

Market Capitalization

$87.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of PolyPid?

The following sell-side analysts have issued research reports on PolyPid in the last twelve months: Citigroup Inc., Craig Hallum, HC Wainwright, Roth Mkm, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for PYPD.

What is the current price target for PolyPid?

0 Wall Street analysts have set twelve-month price targets for PolyPid in the last year. Their average twelve-month price target is $11.67, suggesting a possible upside of 155.8%. Craig Hallum has the highest price target set, predicting PYPD will reach $13.00 in the next twelve months. Roth Mkm has the lowest price target set, forecasting a price of $9.00 for PolyPid in the next year.
View the latest price targets for PYPD.

What is the current consensus analyst rating for PolyPid?

PolyPid currently has 1 sell rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PYPD.

What other companies compete with PolyPid?

Other companies that are similar to PolyPid include Electromed, Carlsmed, Sight Sciences, TriSalus Life Sciences and Treace Medical Concepts. Learn More about companies similar to PolyPid.

How do I contact PolyPid's investor relations team?

PolyPid's physical mailing address is 18 HASIVIM STREET P.O BOX 7126, PETACH TIKVA L3, 4959376. The company's listed phone number is 972-74-719-5700 and its investor relations email address is [email protected]. The official website for PolyPid is www.polypid.com. Learn More about contacing PolyPid investor relations.